Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial
2018 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial
Paschka, P.; Schlenk, R. F; Weber, D.; Benner, A.; Bullinger, L.; Heuser, M. & Gaidzik, V. I et al. (2018)
Leukemia, 32(7) pp. 1621-1630. DOI: https://doi.org/10.1038/s41375-018-0129-6
Documents & Media
Details
- Authors
- Paschka, Peter; Schlenk, Richard F; Weber, Daniela; Benner, Axel; Bullinger, Lars; Heuser, Michael; Gaidzik, Verena I; Thol, Felicitas; Agrawal, Mridul; Teleanu, Veronica; Lübbert, Michael; Fiedler, Walter; Radsak, Markus; Krauter, Jürgen; Horst, Heinz-A.; Greil, Richard; Mayer, Karin; Kündgen, Andrea; Martens, Uwe; Heil, Gerhard; Salih, Helmut R; Hertenstein, Bernd; Schwänen, Carsten; Wulf, Gerald ; Lange, Elisabeth; Pfreundschuh, Michael; Ringhoffer, Mark; Girschikofsky, Michael; Heinicke, Thomas; Kraemer, Doris; Göhring, Gudrun; Ganser, Arnold; Döhner, Konstanze; Döhner, Hartmut
- Issue Date
- 2018
- Journal
- Leukemia
- ISSN
- 0887-6924
- eISSN
- 1476-5551
- Language
- English
